Clinical trials
Brain Diseases trials in Belgium
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
22 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 1 |
| 2021 | 3 |
| 2022 | 2 |
| 2024 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 9 |
| Completed | 7 |
| Active, not recruiting | 2 |
| Withdrawn | 2 |
| Enrolling by invitation | 1 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 2 |
| TauRx Therapeutics Ltd | 2 |
| University Hospital of Mont-Godinne | 2 |
| Xenon Pharmaceuticals Inc. | 2 |
| Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. | 2 |
| BBB-Therapeutics B.V. | 1 |
| Bristol-Myers Squibb | 1 |
| Eli Lilly and Company | 1 |
| Genentech, Inc. | 1 |
| KU Leuven | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Brain Diseases | 22 |
| Central Nervous System Diseases | 12 |
| Nervous System Diseases | 10 |
| Alzheimer Disease | 7 |
| Dementia | 6 |
| Neurodegenerative Diseases | 6 |
| Epilepsy | 4 |
| Seizures | 4 |
| Brain Neoplasms | 3 |
| Central Nervous System Neoplasms | 3 |
Trials
Showing 26 to 22 of 22. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.